Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension

Abstract

Compounds characterized generally as alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula II: wherein q is two or three; wherein r is zero or two; wherein R 2 is selected from hydrido, methyl, ethyl and phenyl; wherein R 3 is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein R 5 is propargyl or a propargyl containing moiety; wherein R 7 is cyclohexylmethyl; wherein R 8 is selected from n-propyl, isobutyl, cyclopropyl, cyclopropylmethyl, allyl and vinyl; and wherein each of R 12 and R 13 is a group independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.

What is claimed is:  
     
         1 . A compound of Formula I:  
       
         
           
           
               
               
           
         
       
       wherein each of R 1  and R 11  is a group independently selected from hydrido, alkyl, alkylaminoalkyl and phenyl; wherein p is a number selected from zero through five, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido and alkyl; wherein R 3  is a group selected from hydrido, cycloalkylalkyl, aralkyl and haloaralkyl; wherein each of R 4  and R 6  is a group independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, cycloalkyl, aryl and aralkyl; wherein each of R 9  and R 10  is a group independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl and aryl; wherein m is a number selected from zero through three; wherein n is a number selected from zero through three; wherein R 7  is a group selected from alkyl, cycloalkylalkyl and aralkyl; wherein R 8  is a group selected from hydrido, alkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, alkenyl and haloalkenyl; wherein each of R 12  and R 13  is a group independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkylacyl, aryl, aralkyl, haloaryl and haloaralkyl; and wherein any one of said R 1  through R 13  groups having a substitutable position may be substituted with one or more groups selected from alkyl, hydroxy, hydroxyalkyl, halo, alkoxy, alkoxyalkyl and alkenyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         2 . Compound of  claim 1  wherein each of R 1  and R 11  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, N,N′-dimethylaminomethyl, N,N′-diethylaminomethyl, N,N′diethylaminoethyl and phenyl; wherein p is a number selected from zero through four, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido and alkyl; wherein R 3  is selected from hydrido, cycloalkylalkyl, phenylalkyl, halophenylalkyl, naphthylalkyl and halonaphthylalkyl; wherein each of R 4  and R 6  is independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, phenyl and benzyl; wherein each of R 9  and R 10  is independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl and aryl; wherein m is a number selected from zero through three; wherein n is a number selected from zero through three; wherein R 7  is selected from cyclohexylmethyl and benzyl, either one of which may be substituted with one or more groups selected from alkyl, hydroxy and alkoxy; wherein R 8  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkenyl and haloalkenyl; and wherein each of R 12  and R 13  is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, halophenyl, phenylalkyl, halophenylalkyl, naphthyl, halonaphthyl, naphthylalkyl and halonaphthylalkyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         3 . Compound of  claim 2  wherein each of R 1  and R 11  is independently selected from hydrido, methyl, ethyl, n-propyl and isopropyl; wherein p is a number selected from zero through three, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido, methyl, ethyl and n-propyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, phenylethyl, fluorobenzyl, fluorophenylethyl, chlorobenzyl, chlorophenylethyl, naphthylmethyl, naphthylethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, cycloalkyl, aryl and aralkyl; wherein m is a number selected from one through three; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, allyl and vinyl; and wherein each of R 12  and R 13  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, propylcarbonyl, ethylcarbonyl, methylcarbonyl, phenyl, benzyl, phenylethyl, monochlorophenyl, dichlorophenyl, monofluorophenyl, difluorophenyl, monochlorophenylmethyl, monochlorophenylethyl, dichlorophenylmethyl, dichlorophenylethyl, naphthyl, monofluoronaphthyl, monochloronaphthyl, naphthylmethyl, naphthylethyl, fluoronapthylmethyl and chloronaphthylethyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         4 . Compound of  claim 3  wherein each of R 1  and R 11  is independently hydrido or methyl; wherein p is a number selected from zero through three, inclusive; wherein r is zero or two; wherein R 2  is selected from hydrido, methyl, ethyl and n-propyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, phenylethyl, phenylpropyl, fluorobenzyl, fluorophenylethyl, chlorobenzyl, chlorophenylethyl, naphthylmethyl, naphthylethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is hydrido; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido and methyl; wherein m is one or two; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from ethyl, n-propyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, allyl and vinyl; wherein each of R 12  and R 13  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethyl, phenyl, benzyl, monochlorophenyl and dichlorophenyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         5 . Compound of  claim 4  of Formula II  
       
         
           
           
               
               
           
         
       
       wherein r is zero or two; wherein q is two or three; wherein R 2  is selected from hydrido, methyl, ethyl and phenyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is hydrido; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido and methyl; wherein m is one or two; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from n-propyl, isobutyl, cyclopropyl, cyclopropylmethyl, allyl and vinyl; wherein R 12  and R 13  is independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         6 . Compound of  claim 5  selected from compounds, their tautomers and pharmaceutically-acceptable salts thereof, of the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         7 . Compound of  claim 6  which is N-[1R*-[[[1S,1R*-(cyclohexylmethyl)-2S*,3R*-dihydroxy-5-methylhexyl]amino]carbonyl]-3-butynyl]-αR*-[[[2-(dimethylamino)ethyl]sulfonyl]methyl]benzenepropanamide or a pharmaceutically-acceptalble salt thereof.  
     
     
         8 . A pharmaceutical composition comprising a therapeutically-effective amount of a renin-inhibiting compound and a pharmaceutically-acceptable carrier or diluent, said renin-inhibiting compound selected from a family of compounds of Formula I:  
       
         
           
           
               
               
           
         
       
       wherein each of R 1  and R 11  is a group independently selected from hydrido, alkyl, alkylaminoalkyl and phenyl; wherein p is a number selected from zero through five, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido and alkyl; wherein R 3  is a group selected from hydrido, cycloalkylalkyl, aralkyl and haloaralkyl; wherein each of R 4  and R 6  is a group independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, cycloalkyl, aryl and aralkyl; wherein each of R 9  and R 10  is a group independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl and aryl; wherein m is a number selected from zero through three; wherein n is a number selected from zero through three; wherein R 7  is a group selected from alkyl, cycloalkylalkyl and aralkyl; wherein R 8  is a group selected from hydrido, alkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, alkenyl and haloalkenyl; wherein each of R 12  and R 13  is a group independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkylacyl, aryl, aralkyl, haloaryl and haloaralkyl; and wherein any one of said R 1  through R 13  groups having a substitutable position may be substituted with one or more groups selected from alkyl, hydroxy, hydroxyalkyl, halo, alkoxy, alkoxyalkyl and alkenyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         9 . The composition of  claim 8  wherein each of R 1  and R 11  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, N,N′-dimethylaminomethyl, N,N′-diethylaminomethyl, N,N′diethylaminoethyl and phenyl; wherein p is a number selected from zero through four, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido and alkyl; wherein R 3  is selected from hydrido, cycloalkylalkyl, phenylalkyl, halophenylalkyl, naphthylalkyl and halonaphthylalkyl; wherein each of R 4  and R 6  is independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, phenyl and benzyl; wherein each of R 9  and R 10  is independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl and aryl; wherein m is a number selected from zero through three; wherein n is a number selected from zero through three; wherein R 7  is selected from cyclohexylmethyl and benzyl, either one of which may be substituted with one or more groups selected from alkyl, hydroxy and alkoxy; wherein R 8  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkenyl and haloalkenyl; and wherein each of R 12  and R 13  is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, halophenyl, phenylalkyl, halophenylalkyl, naphthyl, halonaphthyl, naphthylalkyl and halonaphthylalkyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         10 . The composition of  claim 9  wherein each of R 1  and R 11  is independently selected from hydrido, methyl, ethyl, n-propyl and isopropyl; wherein p is a number selected from zero through three, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido, methyl, ethyl and n-propyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, phenylethyl, fluorobenzyl, fluorophenylethyl, chlorobenzyl, chlorophenylethyl, naphthylmethyl, naphthylethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, cycloalkyl, aryl and aralkyl; wherein m is a number selected from one through three; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, allyl and vinyl; and wherein each of R 12  and R 13  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, propylcarbonyl, ethylcarbonyl, methylcarbonyl, phenyl, benzyl, phenylethyl, monochlorophenyl, dichlorophenyl, monofluorophenyl, difluorophenyl, monochlorophenylmethyl, monochlorophenylethyl, dichlorophenylmethyl, dichlorophenylethyl, naphthyl, monofluoronaphthyl, monochloronaphthyl, naphthylmethyl, naphthylethyl, fluoronapthylmethyl and chloronaphthylethyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         11 . The composition of  claim 10  wherein each of R 1  and R 11  is independently hydrido or methyl; wherein p is a number selected from zero through three, inclusive; wherein r is zero or two; wherein R 2  is selected from hydrido, methyl, ethyl and n-propyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, phenylethyl, phenylpropyl, fluorobenzyl, fluorophenylethyl, chlorobenzyl, chlorophenylethyl, naphthylmethyl, naphthylethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is hydrido; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido and methyl; wherein m is one or two; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from ethyl, n-propyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, allyl and vinyl; wherein each of R 12  and R 13  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethyl, phenyl, benzyl, monochlorophenyl and dichlorophenyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         12 . The composition of  claim 11  wherein said compound is of Formula II  
       
         
           
           
               
               
           
         
       
       wherein r is zero or two; wherein q is two or three; wherein R 2  is selected from hydrido, methyl, ethyl and phenyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is hydrido; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido and methyl; wherein m is one or two; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from n-propyl, isobutyl, cyclopropyl, cyclopropylmethyl, allyl and vinyl; wherein R 12  and R 13  is independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         13 . The composition of  claim 12  wherein said renin inhibitor compound is selected from compounds, their tautomers and pharmaceutically-acceptable salts thereof, of the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         14 . The composition of  claim 13  wherein said renin-inhibitor compound is N-[1R*-[[[1S,1R*-(cyclohexylmethyl)-2S*,3R*-dihydroxy-5-methylhexyl]amino]carbonyl]-3-butynyl]1-αR*-[[[2-dimethylamino)ethyl]sulfonyl]methyl]benzenepropanamide.  
     
     
         15 . A therapeutic method for treating hypertension or glaucoma, said method comprising administering to a hypertensive patient a therapeutically-effective amount of a compound of Formula I:  
       
         
           
           
               
               
           
         
       
       wherein each of R 1  and R 11  is a group independently selected from hydrido, alkyl, alkylaminoalkyl and phenyl; wherein p is a number selected from zero through five, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido and alkyl; wherein R 3  is a group selected from hydrido, cycloalkylalkyl, aralkyl and haloaralkyl; wherein each of R 4  and R 6  is a group independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, cycloalkyl, aryl and aralkyl; wherein each of R 9  and R 10  is a group independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl and aryl; wherein m is a number selected from zero through three; wherein n is a number selected from zero through three; wherein R 7  is a group selected from alkyl, cycloalkylalkyl and aralkyl; wherein R 8  is a group selected from hydrido, alkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, alkenyl and haloalkenyl; wherein each of R 12  and R 13  is a group independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkylacyl, aryl, aralkyl, haloaryl and haloaralkyl; and wherein any one of said R 1  through R 13  groups having a substitutable position may be substituted with one or more groups selected from alkyl, hydroxy, hydroxyalkyl, halo, alkoxy, alkoxyalkyl and alkenyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         16 . The method of  claim 15  wherein each of R 1  and R 11  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, N,N′-dimethylaminomethyl, N,N′-diethylaminomethyl, N,N′diethylaminoethyl and phenyl; wherein p is a number selected from zero through four, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido and alkyl; wherein R 3  is selected from hydrido, cycloalkylalkyl, phenylalkyl, halophenylalkyl, naphthylalkyl and halonaphthylalkyl; wherein each of R 4  and R 6  is independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, phenyl and benzyl; wherein each of R 9  and R 10  is independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl and aryl; wherein m is a number selected from zero through three; wherein n is a number selected from zero through three; wherein R 7  is selected from cyclohexylmethyl and benzyl, either one of which may be substituted with one or more groups selected from alkyl, hydroxy and alkoxy; wherein R 8  is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkenyl and haloalkenyl; and wherein each of R 12  and R 13  is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, halophenyl, phenylalkyl, halophenylalkyl, naphthyl, halonaphthyl, naphthylalkyl and halonaphthylalkyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         17 . The method of  claim 16  wherein each of R 1  and R 11  is independently selected from hydrido, methyl, ethyl, n-propyl and isopropyl; wherein p is a number selected from zero through three, inclusive; wherein r is a number selected from zero, one and two; wherein R 2  is selected from hydrido, methyl, ethyl and n-propyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, phenylethyl, fluorobenzyl, fluorophenylethyl, chlorobenzyl, chlorophenylethyl, naphthylmethyl, naphthylethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is independently selected from hydrido and methyl; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido, alkyl, cycloalkyl, aryl and aralkyl; wherein m is a number selected from one through three; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, allyl and vinyl; and wherein each of R 12  and R 13  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, propylcarbonyl, ethylcarbonyl, methylcarbonyl, phenyl, benzyl, phenylethyl, monochlorophenyl, dichlorophenyl, monofluorophenyl, difluorophenyl, monochlorophenylmethyl, monochlorophenylethyl, dichlorophenylmethyl, dichlorophenylethyl, naphthyl, monofluoronaphthyl, monochloronaphthyl, naphthylmethyl, naphthylethyl, fluoronapthylmethyl and chloronaphthylethyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         18 . The method of  claim 17  wherein each of R 1  and R 11  is independently hydrido or methyl; wherein p is a number selected from zero through three, inclusive; wherein r is zero or two; wherein R 2  is selected from hydrido, methyl, ethyl and n-propyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, phenylethyl, phenylpropyl, fluorobenzyl, fluorophenylethyl, chlorobenzyl, chlorophenylethyl, naphthylmethyl, naphthylethyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is hydrido; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido and methyl; wherein m is one or two; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from ethyl, n-propyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, allyl and vinyl; wherein each of R 12  and R 13  is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethyl, phenyl, benzyl, monochlorophenyl and dichlorophenyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         19 . The method of  claim 18  wherein said compound is of Formula II  
       
         
           
           
               
               
           
         
       
       wherein r is zero or two; wherein q is two or three; wherein R 2  is selected from hydrido, methyl, ethyl and phenyl; wherein R 3  is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein each of R 4  and R 6  is hydrido; wherein R 5  is selected from  
       
         
           
           
               
               
           
         
       
       wherein V is selected from hydrido and methyl; wherein m is one or two; wherein R 7  is cyclohexylmethyl; wherein R 8  is selected from n-propyl, isobutyl, cyclopropyl, cyclopropylmethyl, allyl and vinyl; wherein R 12  and R 13  is independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         20 . The method of  claim 18  wherein said compound is selected from compounds, their tautomers and pharmaceutically-acceptable salts thereof, of the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         21 . The method of  claim 20  wherein said compound is N-[1R*-[[[1S,1R*-(cyclohexylmethyl)-2S*,3R*-dihydroxy-5-methylhexyl]amino]carbonyl]-3-butynyl]-αR*-[[[2-(dimethylamino)ethyl]sulfonyl]methyl]benzenepropanamide.  
     
     
         22 . The method of  claim 15  for treating hypertension.  
     
     
         23 . The method of  claim 15  for treating glaucoma.